# EDGAR Filing Document

**Accession Number:** 0000012239
**File Stem:** 0001213900-26-035035
**Filing Date:** 2026-3
**Character Count:** 12034
**Document Hash:** 55320f9bfbd889f10a675e811f3c4d7e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-035035.hdr.sgml**: 20260326

**ACCESSION NUMBER**: 0001213900-26-035035

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260326

**DATE AS OF CHANGE**: 20260326

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dominari Holdings Inc.
- **CENTRAL INDEX KEY:** 0000012239
- **STANDARD INDUSTRIAL CLASSIFICATION:** SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 520849320
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-52113
- **FILM NUMBER:** 26800647

**BUSINESS ADDRESS:**
- **STREET 1:** 725 FIFTH AVENUE
- **STREET 2:** 22ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** (212) 393-4540

**MAIL ADDRESS:**
- **STREET 1:** 725 FIFTH AVENUE
- **STREET 2:** 22ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AIkido Pharma Inc.
- **DATE OF NAME CHANGE:** 20210111

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aikido Pharma Inc.
- **DATE OF NAME CHANGE:** 20200317

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPHERIX INC
- **DATE OF NAME CHANGE:** 20010815
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hayes Anthony
- **CENTRAL INDEX KEY:** 0001538372

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 1796 SHADY LANE
- **CITY:** COLUMBIA
- **STATE:** SC
- **ZIP:** 29206

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 8)**

**DOMINARI HOLDINGS INC.**

*(Name of Issuer)*

**Common stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Robert Charron**<br>Ellenoff Grossman & Schole LLP,<br>1345 6th Avenue<br>New York NY 10105<br>(212) 370-1300

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/23/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Anthony Hayes** | Name of reporting person<br>**Anthony Hayes** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**9753814.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**9753814.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9753814.00** | Aggregate amount beneficially owned by each reporting person<br>**9753814.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**35.3%** | Percent of class represented by amount in Row (11)<br>**35.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** 1) Of the 9,753,814 shares reported as beneficially owned with sole voting and dispositive power, 116,248 shares reported are indirectly owned by the Reporting Person's Rollover IRA and 9,637,566shares are owned directly by the Reporting Person, including 5,000,000 shares and 2,971 shares underlying stock options, which are exercisable within 60 days upon the filing of a Form S-8 to register the shares of Common Stock subject to the stock option, which was filed on January 9, 2026. The Reporting Person exercises control over the Rollover IRA, and as such, has voting and investment power over the shares held by the Rollover IRA. This excludes an aggregate of 576,368 shares issuable pursuant to certain warrants purchased by the Reporting Person in connection with the Issuer's private placement offering, which are not currently exercisable due to certain beneficial ownership limitations.

(2) Row 13 is calculated based on an aggregate of 27,613,781 shares of Common Stock which includes 22,613,781 shares of Common Stock of the Issuer outstanding as of March 20, 2026 and an aggregate of 5,000,000 shares of Common Stock issuable upon exercise of the stock option held by the Reporting Person under the Issuer's 2022 Equity Incentive Plan.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common stock, par value $0.0001 per share

**(b) Name of Issuer:**
DOMINARI HOLDINGS INC.

**(c) Address of Issuer's Principal Executive Offices:**
725 FIFTH AVENUE, 22ND FLOOR, New York, NY, 10022

EXPLANATORY NOTE This Amendment No. 8 to Schedule 13D (this "Amendment No. 8") is filed to amend the Schedule 13D filed by the Reporting Person with the U.S. Securities and Exchange Commission on December 28, 2023 (the "Initial Schedule 13D"), as amended by Amendment No. 1 to Schedule 13D filed on June 13, 2024 ("Amendment No. 1"), as amended by Amendment No. 2 to Schedule 13D filed on January 3, 2025 ("Amendment No. 2"), as amended by Amendment No. 3 to Schedule 13D filed on February 12, 2025 ("Amendment No. 3"), as amended by Amendment No. 4 to Schedule 13D filed on February 21, 2025 ("Amendment No. 4"), as amended by Amendment No. 5 to Schedule 13D filed on March 25, 2025 ("Amendment No. 5"), as amended by Amendment No. 6 to Schedule 13D filed on April 16, 2025 ("Amendment No. 6"), as amended by Amendment No. 7 to Schedule 13D filed on May 6, 2025 ("Amendment No. 7") and together with the Initial Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 and Amendment No. 5, Amendment No. 6, Amendment No. 7 (the "Schedule 13D"). This Amendment No. 8 supplements and amends the Schedule 13D as specifically set forth herein. Except as amended and supplemented by this Amendment No. 8, the Schedule 13D remains unchanged.

**Item 4. Purpose of Transaction**

Item 4 of the Schedule 13D is hereby amended and supplemented with the following: The transaction giving rise to the filing of this Amendment No. 8 is the Reporting Person grant of 3,000,000 shares of the Issuer's Common Stock pursuant to the 2022 Equity Incentive Plan. Except as disclosed in this Item 4, the Reporting Person has no current plan or proposal which relate to or would result in any of the events described in Items (a) through (j) of the instructions to Item 4 of Schedule 13D. The Reporting Person may, at any time and from time to time, review or reconsider his position and/or change his purpose.

**Item 5. Interest in Securities of the Issuer**

**(a)**
(a)-(b) As of the date hereof, the Reporting Person may be deemed to have beneficial ownership, sole voting power and sole dispositive power with regard to 9,753,814shares of Common Stock, which represents approximately 35.3% of the shares of Common Stock outstanding. This amount includes 116,248 shares that are held indirectly by the Reporting Person's Rollover IRA, and 9,637,566 shares that are owned directly by the Reporting Person, including 5,000,000 shares and 2,971 shares underlying stock options, which are exercisable upon the filing of a Form S-8 to register the shares of Common Stock subject to the stock option, which was filed on January 9, 2026. This excludes an aggregate of 576,368 shares issuable pursuant to certain warrants purchased by the Reporting Person in connection with the Issuer's private placement offering, which are not currently exercisable due to certain beneficial ownership limitations. The foregoing beneficial ownership percentage is calculated based on an aggregate of 27,613,781 shares of Common Stock which includes 22,613,781 shares of Common Stock of the Issuer outstanding as of March 20, 2026 and an aggregate of 5,000,000 shares of Common Stock issuable upon exercise of the stock option held by the Reporting Person under the Issuer's 2022 Equity Incentive Plan.

**(b)**
(b) (a)-(b) As of the date hereof, the Reporting Person may be deemed to have beneficial ownership, sole voting power and sole dispositive power with regard to 9,753,814 shares of Common Stock, which represents approximately 35.3% of the shares of Common Stock outstanding. This amount includes 116,248 shares that are held indirectly by the Reporting Person's Rollover IRA, and 9,637,566 shares that are owned directly by the Reporting Person, including 5,000,000 shares underlying a stock option, which are exercisable upon the filing of a Form S-8 to register the shares of Common Stock subject to the stock option, which was filed on January 9, 2026. This excludes an aggregate of 576,368 shares issuable pursuant to certain warrants purchased by the Reporting Person in connection with the Issuer's private placement offering, which are not currently exercisable due to certain beneficial ownership limitations. The foregoing beneficial ownership percentage is calculated based on an aggregate of 27,613,781 shares of Common Stock which includes 22,613,781 shares of Common Stock of the Issuer outstanding as of March 20, 2026 and an aggregate of 5,000,000 shares of Common Stock issuable upon exercise of the stock option held by the Reporting Person under the Issuer's 2022 Equity Incentive Plan.

**(c)**
The following transactions in the shares of Common Stock were conducted by the Reporting Person within the past sixty (60) days: On January 7, 2026, the Reporting Person was granted 3,000,000 shares of the Issuer's Common Stock pursuant to the 2022 Equity Incentive Plan. The grant was originally subject to stockholder approval of an amendment to the 2022 Equity Incentive Plan, which was obtained on March 4, 2026, and registration of the shares on Form S-8, which occurred on March 13, 2026. On March 18, 2026, instruction of issuance of the shares were sent to the transfer agent, the confirmation of issuance was received on March 23, 2026.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

In his capacity as Chief Executive Officer and Chairman of the Board of the Issuer, the Reporting Person may be entitled to receive cash compensation and equity compensation, including share options or other equity awards, pursuant to the Issuer's 2022 Equity Incentive Plan. Such compensation is based on the Issuer meeting or exceeding certain annual revenue amounts during specified calendar years. The information provided or incorporated by reference in Items 2, 3, 4 and 5 of this Amendment No. 8, is hereby incorporated herein by this reference thereto.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Anthony Hayes

**Signature:** /s/ Anthony Hayes

**Name/Title:** Anthony Hayes/Chief Executive Officer and Chairman of the Board

**Date:** 03/26/2026